HDAC9 and melanoma: Quisinostat (pan-HDAC inhibitor) plus flavopiridol (CDK inhibitor) showed high activities against cutaneous BRAFV600E melanoma cells with acquired BRAF inhibitor resistance (MM249-R and SK-MEL28-R cell lines), which did not differ from their activities against the sensitive parent melanoma cell lines [Table 3][114].